肝病治疗仪穴位疗法联合拉米夫定治疗乙肝失代偿期肝硬化临床疗效分析

目的探讨肝病治疗仪穴位疗法联合拉米夫定治疗乙肝失代偿期肝硬化疗效,为临床治疗提供依据。方法选择收治的失代偿期乙肝肝硬化90例患者,随机分为对照组和干预组,对照组在综合治疗的基础上加用拉米夫定,干预组在对照组治疗基础上,应用肝病治疗仪穴位治疗,1次/d,30 min/次。结果两组治疗后肝功能指标、血清病毒学指标和血流动力学指标均有好转(P<0.05);其中干预组治疗后总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)和Child-Pugh评分均低于对照组(P<0.05);干预组治疗后HBeAg转阴和HBV-DNA转阴分别高于对照组(P<0.05);干预组治疗后门静脉内径(Dpv)、脾静脉内径(Dsv)和门静脉血流量(PVF)分别低于对照组(P<0.05)。结论肝病治疗仪穴位疗法联合拉米夫定治疗乙肝失代偿期肝硬化可以有效提高临床疗效。

The analysis of liver disease therapy instrument combination with lamivudine treatment for 45 decompensated cirrhosis patients due to hepatitis B

Objective To explore the clinical efficacy on liver disease therapy instrument combination with lamivudine treatment for decompensated cirrhosis patient due to hepatitis B.To provide the basis for clinical treatment.Methods 90 patients with decompensated cirrhosis from December 2008 to November 2011 in our hospital were included into this study.They were divided into the control group and the intervention group.The control group was treated with lamivudine on the basis of the comprehensive treatment.The intervention group was treated with liver disease therapy instrument on the basis of the control group,which were performed every 30 minutes once a day.Results The liver function,serum virological indicators and hemodynamic parameters after treatment were better than pre treatment in two group（P 0.05）.The TBIL、ALT、 Child-Pugh in intervention group was lower than that of control group.The differences were significant（P 0.05）;The HBeAg and HBV DNA negative in intervention group was higher than that of control group.The differences were significant（P 0.05）.The Dpv、Dsv、PVF in intervention group were lower than that of control group.The differences were significant（P 0.05）.Conclusion Liver disease therapy instrument combination with lamivudine in the treatment of hepatitis B patients with decompensated cirrhosis can effectively improve the clinical efficacy.